This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Puma, J. A. Articles by Tcheng, J. E. Search for Related Content PubMed PubMed Citation Articles by Puma, J. A. Articles by Tcheng, J. E.

Clinical Characteristics Predict Benefits From Eptifibatide Therapy During Coronary Stenting

Insights From the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) Trial

Joseph A. Puma, DO, FACC^_*,_*, Lesan T. Banko, MD^_*, Karen S. Pieper, MS, Terrence J. Sacchi, MD, FACC^_*, J. Conor O'Shea, MD, Jean Pierre Dery, MD and James E. Tcheng, MD, FACC

^_* New York Methodist Hospital-Cornell Heart Center, Brooklyn New York
Duke Clinical Research Institute, Durham, North Carolina

View larger version (18K): [in a new window]   Figure 1 Flow of patients.

View larger version (19K): [in a new window]   Figure 2 Survival from death or myocardial infarction to 12 months.